FRLN

Freeline Therapeutics Holdings plc

6.40 USD
-0.08 (-1.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Freeline Therapeutics Holdings plc stock is down 0% since 30 days ago. The next earnings date is Apr 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 February’s closed higher than January.

About Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B.